{"id":3534,"date":"2019-05-16T17:50:29","date_gmt":"2019-05-16T08:50:29","guid":{"rendered":"http:\/\/163.180.4.222\/lab\/?p=3534"},"modified":"2019-05-16T18:06:01","modified_gmt":"2019-05-16T09:06:01","slug":"companies-persist-with-biomedical-papers","status":"publish","type":"post","link":"https:\/\/biochemistry.khu.ac.kr\/lab\/?p=3534","title":{"rendered":"Companies persist with biomedical papers"},"content":{"rendered":"

 <\/p>\n

<\/h5>\n
Corporate research in the life sciences endures, despite diminishing in other fields of science.<\/h5>\n

 <\/p>\n

\n
Many advanced countries struggle to increase their productivity. Between 1970 and 2014, real GDP per hour worked, a measure of labour productivity, grew by an average of just 1.62% per year in the <\/span>United States<\/a>, down from 2.82% during the period 1920 to 1970. One suggested reason is that, despite growing investments in research, good ideas are harder to find.<\/span><\/div>\n<\/div>\n
\n
\n

Many sectors have to spend significantly more to merely sustain past levels of innovation. For example, the number of new drugs approved every year by the\u00a0US Food and Drug Administration<\/a>\u00a0between 1970 and 2015 has remained flat despite annual increases in research and development spending (R&D) of 6%.<\/p>\n

 <\/p>\n